Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids?

N. Chaudhuri (Wythenshawe, Manchester, United Kingdom), V. Cottin (Lyon, France), S. Cerri (Modena, Italy), M. Kreuter (Heidelberg, Germany), M. Otaola (Buenos Aires, Argentina), D. Castillo Villegas (Barcelona, Spain), C. Glazer (Dallas, Texas, United States of America), H. Müller (Ingelheim am Rhein, Germany), C. Coeck (Brussels, Belgium), M. Quaresma (Ingelheim am Rhein, Germany), T. Maher (London, United Kingdom)

Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin?
Session: What is new in interstitial lung diseases of known origin?
Session type: Oral Presentation
Number: 4576

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Chaudhuri (Wythenshawe, Manchester, United Kingdom), V. Cottin (Lyon, France), S. Cerri (Modena, Italy), M. Kreuter (Heidelberg, Germany), M. Otaola (Buenos Aires, Argentina), D. Castillo Villegas (Barcelona, Spain), C. Glazer (Dallas, Texas, United States of America), H. Müller (Ingelheim am Rhein, Germany), C. Coeck (Brussels, Belgium), M. Quaresma (Ingelheim am Rhein, Germany), T. Maher (London, United Kingdom). Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids?. 4576

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: